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Accurate spatiotemporal regulation of genetic expression and cell microenvironment are both essential
to epithelial morphogenesis during development, wound healing and cancer. In vivo, this is achieved
through the interplay between intrinsic cellular properties and extrinsic signals. Amongst these,
morphogen gradients induce specific concentration- and time-dependent gene expression changes that
influence a target cell's fate. As systems biology attempts to understand the complex mechanisms under-
lying morphogenesis, the lack of experimental setup to recapitulate morphogen-induced patterning
in vitro has become limiting. For this reason, we developed a versatile microfluidic-based platform to
control the spatiotemporal delivery of chemical gradients to tissues grown in Petri dishes. Using this
setup combined with a synthetic inducible gene expression system, we were able to restrict a target
gene's expression within a confluent epithelium to bands of cells as narrow as four cell diameters with a
one cell diameter accuracy. Applied to the targeted delivery of growth factor gradients to a confluent
epithelium, this method further enabled the localized induction of epithelial–mesenchymal transitions
and associated morphogenetic changes. Our approach paves the way for replicating in vitro the morpho-
gen gradients observed in vivo to determine the relative contributions of known intrinsic and extrinsic
factors in differential tissue patterning, during development and cancer. It could also be readily used to
spatiotemporally control cell differentiation in ES/iPS cell cultures for re-engineering of complex tissues.
Finally, the reversibility of the microfluidic chip assembly allows for pre- and post-treatment sample
manipulations and extends the range of patternable samples to animal explants.Introduction
Tissue patterning is key to morphogenesis during develop-
ment and cancer. Understanding both its genetic and biophys-
ical determinants holds promise to enable the re-engineering
of complex tissues from embryonic (ESC) or induced-
pluripotent (iPSC) stem cells, whether it is for scientific or
medical purposes. To deal with the multi-parametric and
multi-scale nature of developmental patterning and morpho-
genesis, systems biology approaches have been employed.1–3However, progress has been hampered by the lack of suitable
methods to experimentally test theoretical models of develop-
mental and cancer morphogenesis.
During animal embryonic development and tumorigenesis,
epithelia undergo complex morphogenetic transformations
resulting from timed and spatially localized differences in gene
expression. The well-studied vertebrate neural tube formation,
whose failure is the second most common cause of human
birth defects,4 provides many such examples. Localized expres-
sion of shroom family proteins allows neural plate invagina-
tion.5 Localized changes in cadherin expression promote
neural tube closure and neural crest cell emigration.6 Along
the rostral–caudal axis, spatially-restricted cyclic expression
of clock genes drives somitogenesis,7 while neuron progenitors
are patterned along the dorsal–ventral axis.8 Patterning is also
essential post-developmentally to maintain tissue organization/
morphostasis in rapidly turning-over epithelia such as the
colon9 thereby preventing metaplasia.9,10 Upon injury, tissue
healing processes reengage developmental morphogenetic
pathways (e.g. amphibian limb regeneration11).oyal Society of Chemistry 2014
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View Article OnlineTissue patterning, morphogenesis and morphostasis all
rely on a complex interplay between extrinsic chemical or
mechanical signals and intrinsic cellular properties. The best
characterized extrinsic signals are morphogens, signalling
entities that form gradients and induce distinct cellular
responses depending on the dose and duration of target cell
exposure.12 How far morphogens diffuse from their source
depends on their initial concentration, the nature of their
carrier and its binding kinetics to target cells. This versatility
is well illustrated by morphogens of the Hedgehog family
(Hh): Hh production levels vary over time; Hh can be carried
by Hh multimers, lipoproteins, or vesicles; and binding to
various receptors shapes Hh gradients over the field of
exposed cells.8,13,14 Target cells can respond to various dose–
time thresholds, each resulting in a different temporal gene
expression profile and a distinct cell fate.8 Other diffusive
developmental signals and morphostats are expected to act
similarly.10,12 This complex regulation of extracellular signal
propagation and intracellular signal integration gives rise to
precise and robust gene expression patterns but renders mor-
phogen gradient signalling difficult to dissect.
In vivo models have been instrumental in identifying
essential processes that orchestrate morphogenesis and
morphostasis. However, in vivo observations are clouded by
underlying pre-patterns established during earlier develop-
mental stages, and tuning in vivo patterning signals is often
restricted to gross perturbations with poor spatiotemporal
resolution. To gain a true systems understanding of mor-
phogenetic and morphostatic mechanisms, in vitro experi-
mental setups allowing for the exposure of naive tissues to
precisely controlled spatiotemporal concentrations of mor-
phogens are necessary.15 Micropatterning, optogenetics or
LightON can afford various degrees of spatial patterning of
cell subpopulations or timed gene expression induction,16–18
while microfluidic gradient generators can deliver defined
chemical concentrations in a spatially and/or temporally
controlled manner over short periods of time.19–23 However,
the ability of microfluidic methods to control gene expres-
sion through the delivery of chemical gradients in living
tissues has not been demonstrated. Such a setup would
not only allow an in depth dissection of morphogenetic
signalling networks15,24 but also enable re-engineering of
developmental patterns, recapitulation of carcinogenesis,
and the production of complex patterned tissues from ES or
iPSC cells.15,24
Here, we present a versatile microfluidic approach relying
on timed hydrodynamic flow focusing to precisely deliver
gene expression modifier gradients to cells cultured in Petri
dishes, with a one-cell diameter (1 cd) precision over dura-
tions of several hours. As proof of principle, we show how to
pattern gene expression in a monolayer using the broadly
used Tet-On system25 and how to locally induce changes in
gene expression, epithelial polarity and morphology in mono-
layers using spatially restricted perfusion of the diffusive
Hepatocyte Growth Factor (HGF) and Transforming Growth
Factor beta 1 (TGFβ1).This journal is © The Royal Society of Chemistry 2014Methods
Cell line generation and handling
Tet-On Madin-Darby Canine Kidney II cells (MDCK II cells26)
were grown at 37 °C under a 5% CO2 atmosphere in
Dulbecco's modified Eagle medium (DMEM) (high glucose
(4.5 g L−1) + Glutamax without phenol red (Invitrogen,
Paisley, UK)), supplemented with penicillin/streptomycin, 10%
tetracycline-free foetal bovine serum (tet-free FBS, Clontech),
and blasticidin (5 μg mL−1, Merck Biosciences, Nottingham,
UK). The MLC-GFP construct was obtained from Prof Hiroshi
Hosoya27 and cloned into pcDNA4/T0 (Invitrogen). Tet-On
MDCK cells were then transfected with Lipofectamine 2000
(Invitrogen) following manufacturer's recommendations. Cells
were further amplified and subcloned in zeocin (400 μg mL−1,
Merck Biosciences) supplemented medium, in order to
obtain the cell line used in this study, which exhibits very low
levels of MLC-GFP expression in the absence of doxycycline
and very high levels upon doxycycline addition. E-Cadherin was
excised from E-Cadherin pBAT, cloned into EGFP-N1 (Takara-
Clontech, CA, U.S.A), and inserted into the retroviral vector
pRetroQAcGFPN1 (Takara-Clontech). Keratin18-GFP pLNCX
was a kind gift from Prof Rudolf Leube (University of Aachen,
Germany). α-Tubulin was excised from EGFP-C1 and inserted
into the retroviral vector pRetroQAcGFPC1 (Takara-Clontech).
Retroviruses were then generated by transfecting the plasmids
into 293-GPG cells for packaging (a kind gift from Prof Daniel
Ory, Washington University28). Retroviral supernatants were then
used to infect wild type MDCK II cells. Cells were selected in
the presence of 1 mg ml−1 G418 (Merck Biosciences, Nottingham,
UK) (for pLNCX plasmids) or 500 ng ml−1 puromycin (for
pRetroQ plasmids) for 2 weeks and subcloned to obtain
a monoclonal cell line with an epithelial phenotype.Microfabrication
Computer-aided design of microfluidic chip geometries was
done using the AutoCAD 2009 software (Autodesk, Inc.).
Emulsion masks were obtained from JD photo-tools (Oldham,
Lancaster, UK). 3 inch silicon wafers were ordered from
Virginia Semiconductor (Fredericksburg, VA, USA). Moulds were
made from SU-8-2050 photoresist (MicroChem Corp./MCC, MA.
USA) using standard microfabrication techniques.29 They
were then plasma exposed (using a PLASMA clean 4, ILMVAC,
UK), plunged in 1% tridecafluoro-1,1,2,2-tetrahydrooctyl-1-
dimethylchlorosilane (13F, MCC) in toluene for 30 min,
washed, dried and baked at 55 °C for 15 min. Poly-dimethyl,
methylhydrogen siloxane (PDMS) casts were prepared by
mixing 1 : 10 parts of the curing agent to the base Sylgard 184
elastomer (Dow Corning Corp. Midland, MI, USA). The PDMS
mix was degassed and poured onto the 13F-coated patterned
wafer and cured at 55 °C overnight. Then, inputs/outputs
were created using a biopsy punch. For experiments in sealed
chips, PDMS casts were exposed to plasma for 30 s and irre-
versibly bonded to glass coverslips. Finally, the assembled
chips were baked for 15 min at 75 °C. For experiments inLab Chip, 2014, 14, 1336–1347 | 1337
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Ja
nu
ar
y 
20
14
. D
ow
nl
oa
de
d 
on
 0
2/
07
/2
01
4 
10
:5
5:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineclamped chips, PDMS casts were sterilized by 30 s plasma
exposure before use.In silico simulations
Two-dimensional CAD microchip designs were imported
using the MEMS module of Comsol Multiphysics 4.0a
(Comsol, Stockholm, Sweden). Quasi-3D models were gener-
ated using the shallow-channel approximation, considering a
channel height of 80 μm (corresponding to the typical height
of our microfluidic chambers). We used the Navier–Stokes
equations and the model for the transport of diffusive species
to calculate flow dynamics and species concentrations in the
chip under perfusion. Given the microscopic scale and the
aqueous nature of the cell culture medium, the perfused
fluid was considered Newtonian incompressible and in a
laminar regime. Non-slip boundary conditions were applied
to all microchannel walls. We applied laminar flow conditions
at the inlets and outlet. The initial conditions for inlet/outlet
pressures and tubing length corresponded to the values
measured in a typical experiment at steady-state. For each
chip design, flow dynamics and species concentrations were
first determined at steady-state. The treatment width at each
position along the channel was determined choosing a
threshold of 10% of the initial input concentration. In
further simulations, chip performances were compared by
measuring the variation in the treatment width normalized
to the treatment width at the entry of the microchamber
after reaching steady state. The perturbations introduced in
the simulation of chip perfusion were the following:
1) stepped variations in pressure (Fig. 1D): PinputN(t) =
P0inputN + PvarN for 40 s < t < 100 s and PinputN(t) = P0inputN −
PvarN for 100 s < t < 160 s, where P0inputN is the initial base-
line pressure at inlet N and PvarN is the maximum amplitude
of variation allowed at inlet N;
2) periodic low amplitude and short period variations in
all inlets simultaneously (Fig. 1F): PinputN(t) = P0inputN + PvarN ×
sin(2πt/ΔtN), where ΔtN is the perturbation period for inlet N,
1/ΔtN = 1.0 Hz for N = 1, 1.2 Hz for N = 2, 1.1 Hz for N = 3,
1.5 Hz for N = 4, and PvarN = 0.8 × P0inputN/100;
3) a 3 s-long 95% blockage of a microchannel (Fig. 1E)
applied by locally defining a channel depth of 5% the origi-
nal depth (i.e. 4 μm for a 80 μm-deep channel) in the shallow
channel approximation formula. For all simulations, we
chose P0inputN = 18.7 hPa for N = 1 and N = 3, = 18.6 hPa for
N = 2, = 24.2 hPa for N = 4, corresponding to empirically
determined values.In-chip cell culture
MDCK cells from a 95–100% confluent culture in a T75 flask
were resuspended in trypsin/EDTA (TE), washed twice with
culture medium, diluted in culture medium at a concentra-
tion of 50–100 million cells mL−1 and injected into the micro-
fluidic chip through the output. Inputs and outputs were
then blocked and the chips were kept in humid chambers1338 | Lab Chip, 2014, 14, 1336–1347in a 37 °C incubator under a 5% CO2 atmosphere. Cells
were allowed to settle for 4–10 h. Then, 100–200 μL of
fresh medium was perfused through the device. Afterwards,
100–200 μL of fresh medium was perfused every 24 h until
confluence.Perfusion media
All fluorescent dyes were obtained from Life technologies.
Bodipy-TR Ceramide (excited at 633 nm), TRITC (excited at
543 nm), Hoechst 33342 (excited at 405 nm), 10 kDa dextran-
Alexa647 (excited at 633 nm), 3 kDa dextran-cascade blue
(excited at 405 nm) and doxycycline (Sigma-Aldrich) were
dissolved in cell culture medium. All perfusion media were
filtered at 0.22 μm and degassed under vacuum before each
experiment.Perfusion of irreversibly sealed microfluidic chips
We performed preliminary experiments using gravity flow,
a syringe pump (Harvard Apparatus) or a micro-injector
(Narishige IM-300, Narishige, Tokyo, Japan) to regulate inlet
pressures; all failed to provide a stable solution for the paral-
lel perfusion of 3 or more microflows (ESI Fig. S1†). To regu-
late independently the pressure in each inlet and outlet of
the chip, we utilized an 8-channel pressure-driven flow con-
trol system (MFCS-8, Fluigent, Paris, France). To maintain
physiological pH and oxygen levels of the cell culture
medium during perfusion, we used 10% CO2 compressed air
as our pressure source. A custom-made 8-channel holder
hosted the reservoirs containing the perfusion media for each
inlet and outlet. One day after cell confluence was reached
in-chip, each inlet/outlet of the chip was connected to the
appropriate reservoir using sterile tubing extensions of 30 cm
primed with medium. Suitable inlet pressure values were
established empirically, and the inlet delivering the treat-
ment was connected last, ensuring a treatment-free perfusion
setup. Once the closed-loop system was established, the flow
was directly visualized by epifluorescence microscopy and
pressures were adjusted (using the MFCS-8 software) to
obtain the desired flow conditions. Treatment flow was
established by gradually increasing the central input pressure
until the desired treatment width was obtained. Typically,
flow stability was obtained for pressures of ~18 mbar in inlets
1, 2, 3, ~24 mbar in inlet 4 and ~8 mbar in the outlet. In all
of the experiments presented here, we used inlet 2 to deliver
the treatment and inlets 1 and 3 to adjust the position of
the treatment flow (flow focusing). In the Z-plane of the maxi-
mal signal intensity, confocal flow-imaging was calibrated
using the inlet fluorescence to define saturation levels and
the fluorescence outside the microchannels to determine
the background levels and adjust the offset. Using these
imaging settings for the ROI, treatment width was controlled
visually by varying the pressure applied to inlet 2 (typically
within ±1.5 mbar from pressures in inlets 1 and 3). Intended
treatment width was defined by superimposing a scale barThis journal is © The Royal Society of Chemistry 2014
Fig. 1 Setup and optimization of the microfluidic-imaging platform for hydrodynamic cell patterning. (A) Schematic illustration of the experimental
setup. Cells were grown to confluence in-chip. Reservoirs containing perfusion media were independently pressurized, using a pressure-driven
flow control system. Live-imaging was performed simultaneously to enable the visual assessment of the position and width of the treatment flow.
(B) Chip designs tested in silico. (C) Effect of the chip design on the concentration gradient shape under steady-state conditions. Half of the con-
centration gradient across the channel width is plotted. Design “a” leads to the steepest gradient while design “d” leads to the shallowest. (D)
Impact of step-changes in pressure on treatment flow positioning. Design “a” leads to the largest deviation while designs “d/e” lead to the
smallest. (E) Effect of sheath flow blockage on treatment flow positioning. Design “b” leads to the largest deviation while designs “d/e” lead to the
smallest. (F) Impact of pressure micro-oscillations on treatment flow positioning. Design “c” leads to the largest deviation while designs “e” leads
to the smallest. (G) Optimized chip design. (H) Magnification of the treatment-flow stabilization zone. (I) Kymograph of treatment flow reveals that
the maximum amplitude of experimentally observed oscillations is 20%, which leads to a less than 3% increase in the average treatment width.
ROI: region of interest.
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View Article Online(using the Olympus acquisition software F10-ASW viewer) on
acquired images. Post-treatment analysis of treatment flow
imaging allowed precise calculation of the input treatment
width (see below).Preparation of cell monolayers for perfusion with reversibly
sealed chips
5 cm-diameter glass-bottom dishes were spin-coated with a
~100 μm thick PDMS layer (1 : 15 parts of the curing agent to
the elastomer base), and baked overnight at 55 °C. After
plasma cleaning, the dishes were coated with 10%
aminopropyl-triethoxy-silane (APTES)/ethanol, followed by a
3%-glutaraldehyde/PBS treatment, and finally coated withThis journal is © The Royal Society of Chemistry 201410 μg mL−1 type I collagen (R&D Systems) in PBS, according
to the published procedures for covalent binding of collagen
to PDMS.30 Following extensive washes with the cell culture
medium, cells were seeded on the dishes and further handled
using standard procedures.
Perfusion of reversibly sealed microfluidic chips. To
achieve reversible tight seals between microfluidic chips and
cells growing on Petri dishes, we designed a clamp adapted
from Tkachenko et al.31 (Fig. 4A). Glass-bottom dishes
containing 100% confluent cell monolayers were fitted into
the clamp holder interfaced to the confocal imaging platform
stage. The microfluidic chip was affixed to the upper half of
the clamp and connected to the reservoirs and the flow-
control system. The tubing and the chip were primed withLab Chip, 2014, 14, 1336–1347 | 1339
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View Article Onlinethe medium, and pressures were adjusted to keep inlets/
outlet wetted. The two halves of the clamp were then assem-
bled carefully to avoid trapping air bubbles between the chip
and the cell layer. Using the thumb screws, the chip was
slowly brought into contact with the cell layer until a suffi-
ciently tight seal was obtained. A very slight leakage was
allowed to take place to minimise the mechanical stress
applied by the PDMS chip to the cells outside of the micro-
channels while still maintaining a sufficiently tight seal for
flow focusing. Leakage was visually confirmed by the pres-
ence of very faint fluorescence outside the microchannels.
Then, pressures were adjusted for each inlet/outlet to allow
the desired treatment to start. Pressure values necessary for
flow focusing were in the same range as for the closed-chip
experiments, further confirming correct sealing of the chip.
Cell treatment and imaging protocol
The treatment protocols included three phases. During the
equilibration phase (10–30 min), the flow was monitored
directly by epifluorescence imaging to ensure flow stability.
During the treatment phase (lasting from 1 h 30 min to 7 h
depending on the experiment), confocal images were acquired
automatically to monitor the treatment flow width and position
over time. For the washout phase (30–60 min), pressures in
inlets 1–3 were reduced and pressure in inlet 4 increased so
that the flow from inlets 1–3 disappeared and the doxycycline-
free medium could remove residual doxycycline from the chan-
nel. The absence of fluorescence in confocal images taken
during that time proved the efficiency of the washout phase.
To allow post-treatment analysis of the flow and cell staining
dynamics, we used a time-lapse protocol in which time-series
of XY flow imaging (at the plane of maximal flow fluorescence
intensity) alternated with high-resolution Z-stack acquisitions
of cell staining by the fluorescent vital dyes (ceramide and
Hoechst 33342). Imaging was performed on an inverted
microscope IX81 (Olympus Corp., Tokyo, Japan) equipped with
the FV1000 scanning confocal system (Olympus) housing 405,
488, 543, and 633 nm lasers. Brightfield and fluorescence
confocal live-imaging of ~1600 × 600 μm2 portions of the
microfluidic device was achieved through a 10× dry UPlanSApo
(0.40 NA, Olympus), acquiring images every 30 s for time-lapse
movies at 1024 × 384 pixel2, and at 2048 × 768 pixel2 every
3 μm for Z-stack acquisitions, allowing for individual cell mem-
branes to be resolved. Higher magnification images were
acquired through a 40× dry UPlanSApo (0.90 NA, Olympus).
Red (543 nm) and far red (633 nm) fluorescent dyes were
favored for time-lapse flow monitoring to limit phototoxicity
during cell treatments.
Acute doxycycline treatment optimization and analysis
Doxycycline (Sigma-Aldrich) was diluted in sterile distilled
water, aliquoted at 1 mg mL−1, and stored frozen, protected
from light. Cells seeded in 24-well plates (BD Biosciences)
were grown to confluence. 24 h after confluence, wells were
exposed to 0, 5, 10, 20, 40, 80 ng mL−1 of doxycycline in1340 | Lab Chip, 2014, 14, 1336–1347culture medium for durations of 1 h, 3 h, 4 h or 24 h. After
doxycycline exposure, cells were washed three times for 5
min with doxycycline-free culture medium. 24 h after expo-
sure, cells were washed once with a doxycycline-free medium
to remove debris, and MLC-GFP expression was imaged at 3
different positions (each covering ~1.5 × 1.5 mm2), for
each condition. MLC-GFP intensity was measured at 6 differ-
ent positions per image (each covering 200 × 200 μm2). Dose–
response curves were plotted from those measurements and
fitted with sigmoid functions constrained between 0% and
100% using GraphPad Prism (GraphPad Software, CA, USA),
allowing us to determine the minimal concentration of
doxycycline at which 50% of the maximal GFP intensity
signal is reached at 24 h post-exposure for acute treatments
of 1 h 30 min, 3 h 15 min, 4 h 30 min and for a continuous
treatment of 24 h.Determination of effective input and expected output widths
To determine the concentration profile of unlabelled doxycy-
cline (MW = 444 g mol−1) at the ROI during treatment, we
imaged TRITC (MW = 443 g mol−1) fluorescence intensity
under identical flow conditions, or simultaneously with doxy-
cycline treatment. Averaged TRITC fluorescence intensity
values at the ROI were normalized based on fluorescence
intensities at the inlet. Knowing that the inlet doxycycline
concentration was fixed at 1 μg mL−1, we converted fluores-
cence intensities to equivalent doxycycline concentrations
(see Fig. 3F, ESI S4, S7†), giving us an expected doxycycline
concentration profile at the ROI. Threshold doxycycline con-
centrations were determined from doxycycline treatments
performed on Petri-dish-grown monolayers (see previous par-
agraph). The effective input width was then determined by
measuring the distance between the two abscissa coordinates
for which the corresponding doxycycline concentration was
equal to the threshold dose. The output width was deter-
mined as illustrated in Fig. 3 and ESI Fig. S7,† by considering
the average width of the monolayer that expresses >50% of
the maximal MLC-GFP intensity within the treated region. A
Matlab (Mathworks, Natick, MA, USA) routine was used to
automatically measure the effective input and output widths
at each x coordinate along the ROI. Average cell sizes (ESI
Fig. S7D†) were determined by measuring at least 12 rows of
15–20 cells (i.e. >180 cells) per experiment, using the 24 h
post-treatment images. Using all those data, we evaluated the
correlation between effective input and output widths
expressed in microns or in cell diameters using linear regres-
sion, as a measure of the predictability of our technique
(Fig. 4C and ESI S7E–F†). Those results were plotted using
the GraphPad Prism software.TGFβ1 and HGF treatments
Growth factors solutions were diluted in FBS-free culture
medium at 100 ng mL−1, warmed-up to 37 °C and degassed
for 30 min before perfusion.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineImmunostaining
In-chip staining was performed by carefully perfusing media
through the chip output. Cells in-chip or in Petri dishes were
rinsed with fresh FBS-free DMEM medium, fixed at room-
temperature (RT) for 20 min in PBS :DMEM containing
1.75% paraformaldehyde + 1% sucrose + 0.5% Triton-X,
followed by a PBS wash and 10 min incubation at 4 °C in
PBS–BSA 1%. Primary antibodies or rhodamine–phalloidin
were prepared in PBS containing 10 mg ml−1 BSA and applied
for >4 h at 4 °C, followed by three 5 min washes with
PBS–BSA 1% at 4°C, and 1 h-secondary antibody incubation
at RT. Then, a 5 min PBS–BSA 1% with 0.1 μg mL−1 Hoechst
33342 incubation step was followed by three additional
PBS–BSA 1% washes before PBS–BSA 1% was substituted with
an anti-photobleaching solution (Fluorsave, Calbiochem) for
1 h at 37 °C. Polyclonal rabbit anti-ZO1 (Life technologies)
was used at 1 : 50; monoclonal mouse anti-α-tubulin (Life
technologies) was used at 1/300; rhodamine–phalloidin (Life
technologies) was diluted at 1 : 200. Secondary antibodies
were used as follows: Alexa647 goat anti-rabbit 1 : 200, and
TexasRed donkey anti-mouse 1 : 50.Results and discussion
In designing our approach, we were guided by the physiologi-
cal characteristics of morphogen gradients and practical
considerations for in vitro use. In vivo, growth factor and
morphogen gradients span distances from one to tens of cell
diameters (twenty to hundreds of microns32), persist for tens
of minutes to days, and have a precision down to 1 cd.32
Therefore, our approach needed to enable the delivery of a
chemical signal to cells with an accuracy better than one cell
diameter over durations of several hours. A second constraint
was to render the technique compatible with samples that
cannot be readily introduced into or grown in sealed micro-
fluidic channels, but have been successfully grown on Petri-
dishes, such as ESCs, iPSCs and animal tissue explants.Computational optimization of microfluidic chip design
Microfluidic devices represent an attractive technological
solution because they allow for the creation of chemical gra-
dients across large areas with high accuracy, even enabling
the exposure of different parts of the same cell to different
chemical environments.33 To date, microfluidic devices have
primarily been used with high spatial accuracy for durations
<35 min33 or with low spatial accuracy for several hours.34
Positioning accuracy and stability of microfluidic gradients
essentially depend on the flow control system and the design
of the microfluidic chip. To assess the robustness of gradient
positioning, we utilized microfluidic devices that generate
three main streams, and observed stream boundaries over
time under test conditions. The simplest device consists of
three inlets converging into one channel (ESI Fig. S1A†), inThis journal is © The Royal Society of Chemistry 2014which streams flow side-by-side without intermixing due to
the short length-scales and low flow-rates involved. Diffusion
of solutes can however occur at the interfaces between
streams, a phenomenon known as lateral diffusion. In our
experiments, we perfused fluorescent solutions through the
central stream and imaged their position in the region of
interest (ROI) over durations up to 8 h by confocal fluores-
cence microscopy. After testing several flow-control systems
and rejecting those generating too large oscillations in the
position of the stream (ESI Fig. S1B†), we settled for a closed-
loop pressure-controlled device that independently pressur-
izes each inlet and outlet (Fig. 1A, ESI S1C†). Nevertheless,
experimentally, flow disturbances occasionally occurred due
to debris, air bubbles, and pressure oscillations. Therefore,
we sought to optimize the chip design using computational
fluid dynamics modeling of diffusive chemical species within
the channel. For each design (Fig. 1B), we evaluated gradient
steepness (Fig. 1C) and robustness versus local blockage and
pressure changes in one or all inlets (Fig. 1D, E, F). To com-
pare the performance of all designs, we plotted the maximum
change in the width of the treated area (“treatment width”,
i.e. the area exposed to a concentration >10% of the maxi-
mum concentration) in response to perturbations that
diverted the treatment flow (Fig. 1G–H), and made it tran-
siently span a larger area than intended. Overall, treatment
width variations in response to experimental perturbations
were minimized in designs in which the sheath flow was
split into many parallel microflows (Fig. 1H, ESI Fig. S2†)
and in which the treatment flow widened shortly prior to
convergence with the sheath flow (Fig. 1D–F). Hence, in our
simulations, the chip with the optimal design (Fig. 1G–H)
reduced maximum treatment width variations to less than
20% upon any experimental perturbation (Fig. 1D–F). Four
hour long experimental perfusion of a soluble dye through
this chip confirmed that transient maximum variations in
the treatment width did not exceed 20% (Fig. 1I), leading to
an average treatment width increase of less than 3% over
the total duration of the experiment.Optimized devices allow stable, accurate, long term delivery
of chemical gradients to cells
Having optimized chip design, we experimentally tested the
ability of our setup to accurately deliver chemicals through
the apex of epithelial cells grown to confluence in-chip
(Madine-Darby Canine Kidney cells, MDCK, ESI Fig. S1D†).
We used two cell-permeant vital dyes simultaneously: the
blue-fluorescent DNA intercalant Hoechst 33342 and a far-red
fluorescent ceramide probe, for live imaging of cell nuclei
and membranes, respectively. During experiments, we contin-
uously imaged the treatment flow by confocal microscopy
using the fluorescence from the ceramide dye (imaged ROI
shown in Fig. 1G). In a representative experiment, following
4 h 30 min exposure to a 23 μm-wide treatment stream
(or 1.1 cd wide, Fig. 2A, ESI S3A–C†) and subsequent washoutLab Chip, 2014, 14, 1336–1347 | 1341
Fig. 2 Visualization of the treatment width using fluorescent dyes.
(A) Correspondence between the input flow width and the cell labeling
width. The effectively treated region (revealed by the fluorescence
of ceramide in cells, A2) is wider than the width of the treatment
flow (visualized by the fluorescence of ceramide in flow, A1), due
to ceramide diffusion within the membranes of cells partially exposed
to the treatment (A5). The cell permeant dye Hoechst 33342 displays
intercellular diffusion outside the treated region (A3, A6). (B) Line scan
across A4 showing the width of the treatment flow (green), the width
of monolayer labeling with ceramide (red), and the width of nuclear
labeling (blue). (C) Comparison of the diffusion of ceramide and
Hoechst within the cell monolayer up to 22 h after treatment. The
ceramide stain was well retained by treated cells while the Hoechst
stain spreads to the whole monolayer. (D) Line scans across C
immediately after cessation of treatment and 22 h after.
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View Article Onlineof the unbound vital dyes, ceramide stained a 57 μm-wide
(or 2.5 cd wide) strip, a width larger than the treatment flow
due to marker uptake by partially exposed cells (Fig. 2A5, B)
but significantly narrower than the DNA labeling, which
extended up to 92 μm (Fig. 2A6, B). This difference in the
treatment width between two dyes of a similar molecular
weight (Hoechst: 615 g mol−1, Ceramide: 706 g mol−1) resulted
from the combination of two phenomena: 1) the greater
lateral diffusion of Hoechst 33342 across stream boundaries,
and 2) the diffusion across cell walls within the cell mono-
layer, as the Hoechst stain kept spreading during the washout
(ESI Fig. S3C†). Observation of the cells at 24 h post-treatment
further confirmed the good retention of ceramide in treated
cells and the spreading of the Hoechst stain through the
whole monolayer (Fig. 2C, D). It highlighted the importance
of carefully selecting dyes for flow and cell-tracking purposes
in our setup. To select the best dye for flow position tracking,1342 | Lab Chip, 2014, 14, 1336–1347we next observed lateral diffusion along the chip for various
fluorescent markers with molecular weights ranging from
0.3 to 2000 kDa (ESI Fig. S4A–C†). A good agreement was
found between the molecular weight and the treatment
flow width, with the exception of ceramide, whose hydropho-
bicity likely accounted for its very low lateral diffusion,
making it an excellent reporter for the treatment flow position
(ESI Fig. S4C†). Therefore, in subsequent experiments, we
utilized fluorescent ceramide to follow the position of the
treatment flow over time and to highlight treated cells for
hours post-treatment.Conditional gene expression can be predictably and locally
induced within a sealed chip
Next, we evaluated the ability of our platform to apically
deliver a chemical gradient to predictably induce gene expres-
sion in a target region of a cultured epithelium. In vivo,
morphogen-induced gene expression changes are not a sim-
ple readout of the input morphogenetic gradient, but result
from the integration of the gradient by complex transduction
pathways over time (ESI Fig. S5A–B†). Hence, to determine
the relative contributions of the gradient dynamic shape
(“input signal”) and the intracellular transduction pathway
(“transfer function”) to the target cell response (“output”),
one has to be able to separate both components. As we saw
earlier (Fig. 2), for any biochemical treatment, in-flow treat-
ment (“input”) differs from the effective treatment (“cell-level
input”), which depends on the treatment chemical binding
and diffusion within the cell layer. To test our chemical gra-
dient delivery method's reliability, we needed to be able to
predict the effective treatment width from in-flow treatment
imaging.
We therefore needed an input signal that translates into a
cellular output through a simple transfer function. To answer
these needs, we used the Tet-On system, where addition of
the cell-permeant doxycycline above a concentration/time
threshold activates a genetically encoded transactivator that
specifically induces the transcription of transgenes driven
by tet-responsive promoters (ESI Fig. S5C†).25 Hence, the
Tet-On mechanism functions as a “simplified morphogen
signaling pathway” without any intracellular transduction
or feedback steps (ESI Fig. S5D†). We thus generated a
Tet-On MDCK cell line that expresses myosin light chain
(MLC) fused to a green-fluorescent protein (GFP) upon
doxycycline treatment, and grew it to confluence in-chip.
A 3 h 15 min-long local perfusion of ceramide and doxycycline
yielded a narrow band of MLC-GFP expressing cells that
persisted for over 48 h (Fig. 3A–E, ESI S3D–F†), proving that
local induction of gene expression can be achieved with
our setup.
We then determined if the width of the band of cells
expressing GFP above half-maximal levels (output), could be
predicted from the width of the treatment flow (input). GFP
induction extended beyond the region exposed to ceramideThis journal is © The Royal Society of Chemistry 2014
This journal is © The Royal Society of Chemistry 2014
Fig. 3 Microfluidic delivery of chemical inducer gradients allows
spatiotemporal control of gene expression in sealed chips. (A) Chip
setup and regions of interest (ROI). (B–C–D) Extent of MLC–GFP and
ceramide fluorescence, immediately after (B), 24 h after (C) and 48 h
after (D) acute local doxycycline treatment, in a sealed chip. (E)
Comparison between input and output normalized fluorescence
intensity profiles at the ROI at 3 h, 24 h and 48 h post treatment. (F–I)
Determination of the effective input width and the expected output
width. (F) The TRITC fluorescence gradient across the channel
averaged over the duration of the treatment used to estimate the
doxycycline gradient. (G) Doxycycline/GFP dose–response curves used
to determine the threshold doxycycline concentration for half maximal
MLC–GFP fluorescence 24 h post-treatment for each treatment dura-
tion. (H) Prediction of the output width (MLC–GFP expression) from the
effective input width (inferred from the TRITC fluorescence gradient).
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View Article Online(Fig. 3E), as expected given that doxycycline is a 444 g mol−1
hydrosoluble chemical and the amphiphilic 706 g mol−1 cer-
amide probe was shown to display the least lateral diffusion
(ESI Fig. S4C†). We thus experimentally estimated the con-
centration profile of doxycycline from the concentration pro-
file of tetramethyl-rhodamine iso-thiocyanate (TRITC, MW =
443 g mol−1, ESI Fig. S4†) in the ROI under perfusion conditions
identical to our experiment and normalized fluorescence to
that at the inlet (Fig. 3F, ESI S4D–G†). We next determined,
under our experimental conditions, the doxycycline concen-
tration above which GFP-induction is half-maximal (threshold
concentration). As both duration and dose of exposure influ-
ence induction thresholds, we exposed confluent monolayers
to several doxycycline concentrations for various durations
yielding dose–response curves (Fig. 3G, ESI S6†). Using these
curves, we determined that for a 3 h 15 min treatment the
threshold concentration was 7.7 nM. Using this value and the
estimated doxycycline concentration profile at the ROI, we
estimated the effective input width to be 76.2 μm (Fig. 3F).
Taking into consideration cells partially exposed to above
threshold doxycycline concentrations (accounting, on average,
for an additional 0.5 cd on each side of the treated region
with 1 cd = 22.2 μm, Fig. 3H), we then predicted an output
width of 98.4 μm. Imaging of the ROI at 24 h (Fig. 3C) and
48 h (Fig. 3D) post-treatment revealed the steady induction
of MLC-GFP expression in a 102 μm-wide band (Fig. 3E),
comparable to our estimated output width. This result showed
that the output width can be predicted from the input width
by using a fluorescent probe with similar hydrodynamic
properties to the chemical inducer.Reversible chip clamping increases versatility without
affecting treatment accuracy
However, many cells are not readily grown in microfluidic
chips because of their growth requirements in terms of cell
density, medium homeostasis and substrate properties.
Moreover, hard coated glass surfaces are not natural sub-
strates for cell cultures, inducing the formation of long ven-
tral actin stress fibers, structures rarely present in vivo.35
Biological 3D-gels are more suitable substrates for morpho-
genetic studies, because they recapitulate the chemical and
mechanical properties of natural substrates,36 but they are
difficult to set in a chip. To circumvent the limitations of our
setup, we therefore adapted a previously described clamping
device31 to allow enclosure into microfluidic channels of
animal tissue explants or cells cultured on their favorite
substrate in glass-bottom Petri dishes (Fig. 4A).
To maintain a tightly sealed chip without breaking
the glass coverslip, we added a transparent PDMS cushion
layer below the cell layer. To “mask” the PDMS surface to
the cells, we used a protocol that improves substrate surface
coating.30 We thus grew MDCK cells on thin collagen 3D gels
set onto the PDMS cushion (Fig. 4A). The combination of
the soft PDMS cushion and the collagen gel also preventedLab Chip, 2014, 14, 1336–1347 | 1343
Fig. 4 Reusable clamped chips allow versatile control of gene
expression. (A) Schematic illustration of the clamped chip for localized
treatment of cells grown on Petri dishes. (B) Localized MLC–GFP
expression after 24 h under three treatment conditions in clamped
devices. Pink and green dotted lines delineate effective input and
output widths, respectively, inferred from the in-flow TRITC imaging
and MLC–GFP fluorescence intensity. (C) Correlation between effective
input and output widths expressed in cell diameters (cd). Dotted lines
denote the 95% confidence interval.
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View Article Onlinecells outside of the microchannels from being crushed
during clamping, thereby avoiding release of apoptotic or
necrotic factors. Under those conditions, cells were well
polarized, as shown by E-cadherin–GFP and ZO-1 apical junc-
tion staining. Using this setup on MLC–GFP expressing cells
under a range of treatment conditions, we showed that the
output width correlated linearly with the effective input width
(Fig. 4B, C, ESI S7†). Knowing the input width, we could pre-
dict the width of gene expression with a <1 cd accuracy
(Fig. 4C). Together, these data indicated that reversible
clamping maintains patterning precision while allowing users
to retain established culture protocols and post hoc characteri-
zation methods.Morphogenetic changes can be locally triggered by targeted
growth factor treatments
Having established a method to induce spatially restricted
gene expression through the controlled delivery of chemical
gradients to confluent cell cultures, we sought to locally
induce an endogenous genetic program leading to morphoge-
netic changes by exposure to growth factor gradients.
One widely studied morphogenetic process in vitro is Epi-
thelial to Mesenchymal Transition (EMT), which occurs dur-
ing development, wound healing, and epithelial cancers.37,38
EMT is triggered by growth factors that modify the cytoskele-
ton and polarity gene expression dynamics, resulting in cell1344 | Lab Chip, 2014, 14, 1336–1347polarity, cell shape and cell motility changes which are
revealed by the mislocalisation of apical junction markers,
loss of primary cilia, and cell emigration outside the epithe-
lial layer. Depending on the cell type and conditions of
induction, EMT leads to an array of phenotypes ranging from
rounded “somewhat-polarized” cells to flattened highly
motile mesenchymal-like cells.37–40 In MDCK cells, long-term
exposure (>24 h) to TGFβ1 leads to loss of epithelial polarity
and cell spreading,41 while exposure to HGF leads to tubulog-
enesis which maintains some cell polarity.42,43
First, we verified that such phenotypes were observed in
confluent polarized MDCK cells cultures grown on 3D
collagen-coated Petri dishes. A 24 h-exposure to 10 ng mL−1
TGFβ1 led to cell scattering and crawling on the monolayer,
while a 24 h-exposure to 10 ng mL−1 HGF resulted in globular
protuberances characteristic of the tubulogenesis onset
(ESI Fig. S8A†). Though in vitro EMT has traditionally been
studied using global stimuli on subconfluent cell mono-
layers, in vivo, growth factor gradients ensure that only a
subset of cells undergoes EMT within a fully confluent
polarized epithelium. We therefore aimed to induce localized
EMT events within a mature epithelium by acutely applying
growth factor gradients generated with our setup. To ensure
local maximal concentrations above induction threshold at
the ROI under transient treatment conditions (<8 h), input
growth factor concentrations were fixed at 100 ng mL−1 (i.e.
10 times the induction threshold for a 24 h exposure). Upon
localized HGF treatment, MDCK monolayers cultured on
glass (Fig. 5A–B) or on collagen gels (Fig. 5C–G), formed pro-
tuberances in the treated area only (Fig. 5B, E–G, ESI S9†).
E-cadherin–GFP fluorescence levels significantly and specifi-
cally increased in HGF treated cells within 18 h (Fig. 5C–D,
ESI S9†), leading to an accumulation of cytoplasmic
E-cadherin–GFP without detectable loss of junctional
E-cadherin–GFP. In protuberances formed on ciliated conflu-
ent monolayers, apical ZO1 staining was often maintained
(Fig. 5F–G), whereas primary cilia were locally missing,
as revealed by the lack of acetylated-α-tubulin antibody
staining (Fig. 5G). Hence, apical polarity was partially
maintained in HGF treated cells, consistent with previous
studies.42,43 TGFβ1 treatment led to cell scattering on glass
substrates, with treated cells leaving the monolayer or
the treated area (Fig. 5H), eventually forming small protu-
berances (Fig. 5I). On ciliated confluent monolayers grown
on collagen gels, TGFβ1 treatment led to the formation
of protuberances similar to those induced by HGF, but
with a clearly deficient ZO1 staining and fully devoid of
primary cilia44 (Fig. 5J), revealing a more severe loss of apical
polarity similar to what is observed in pancreatic tumors
in situ.45 TGFβ1 also led to a clear relocalization of junc-
tional E-cadherin–GFP to the cytoplasm (ESI Fig. S10†), as
previously reported.46,47 Hence, local acute treatment of
MDCK cells with either HGF or TGFβ1 recapitulated each
type of EMT in the target area only. These results validate our
technique for studying local morphogenetic changes induced
by spatiotemporally controlled growth factor gradients.This journal is © The Royal Society of Chemistry 2014
Fig. 5 Local morphogenetic changes are induced by localized exposure to growth factor gradients. (A) Schematic illustration of the chip and live-
imaging at 24 h of a subconfluent monolayer grown on glass in a sealed-chip and locally exposed for 4 h to a 100 ng mL−1 HGF treatment. Arrow-
heads indicate atypical protuberances only observed in the treated area stained with ceramide. (B) Maximum projections and 3D-rendering of a
protruding group of treated cells. (C) Live-imaging at 4 h and 18 h of a confluent monolayer grown on a collagen gel in a clamped-chip and locally
exposed for 4 h to a 100 ng mL−1 HGF treatment. Cytoplasmic E-cadherin–GFP levels are increased in HGF-treated cells 18 h post-treatment. (D)
Line scan across C at 4 h and 18 h post treatment. (E) Treated cells form a protrusion at 2 days post-treatment in the region imaged in C–D.
E-cadherin–GFP remained at the apical intercellular junctions. (F) 3D-rendering of a multicellular protrusion induced by HGF exposure stained for
ZO-1 (24 h after treatment). ZO-1 remained localized to apical intercellular junctions. (G) Maximal projection of a protrusion induced by exposure
to HGF (24 h after treatment of a confluent ciliated MDCK monolayer). Anti-acetylated α-tubulin staining reveals a lack of primary cilia on the pro-
truding cells. Panels G2′ to G5′, and G2′′ to G5′′ are magnifications of the boxed areas, respectively, marked with ′ and ′′ in G1. (H) Schematic illus-
tration of the chip and live-imaging at 4 h and 24 h of a subconfluent monolayer grown on glass in a sealed-chip and locally exposed for 4 h to a
100 ng mL−1 TGFβ1 treatment. Arrowheads indicate cells and group of cells strongly labeled with ceramide that have emigrated from the treated
area. Asterisks identify areas in which treated cells detached, leaving gaps in the monolayer. (I) 3D-rendering of a portion of the treated area where
cells have protruded above the monolayer. (J) Protrusion induced by exposure to TGFβ1 24 h after treatment of a confluent ciliated MDCK mono-
layer. The protruding cells lost their primary cilia as revealed by anti-acetylated-α-tubulin antibody and ZO1 staining, while retaining some
E-cadherin–GFP at apical intercellular junctions. Panels J2′ to J6′, and J2′′ to J6′′ are magnifications of boxed areas ′ and ′′ in J2–6, respectively.
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View Article OnlineConclusions
By combining long-term hydrodynamic flow-focusing and
conditional gene-expression in a clamped microfluidic chip,
we predictably induced gene-expression in strips of cells
down to ~4 cd-wide with high precision (<1 cd) withinThis journal is © The Royal Society of Chemistry 2014epithelia cultured in Petri-dishes. This approach enables spa-
tial control of gene expression with a one-cell diameter accu-
racy in virtually any existing chemically inducible adherent
cell line. The successful local induction of EMT by HGF and
TGFβ1 treatments further demonstrated that the delivery of
spatiotemporally defined growth factor gradients to culturedLab Chip, 2014, 14, 1336–1347 | 1345
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View Article Onlinetissues can be used to recapitulate in vitro natural morpho-
genetic patterns relevant to developmental organogenesis
and cancer. The reversible assembly of the microfluidic chip
confers several key advantages. First, it makes this patterning
technique compatible with any adherent tissue that can be
grown in a Petri dish, and does not require any further opti-
mization of culture conditions, allowing application to pri-
mary cultures, iPS and ES cells, or animal explants. Second,
it can be combined with substrate micropatterning and
optogenetics to achieve very complex patterning. Third, it
allows pre- and post-patterning treatments such as substrate
engineering, successive localized treatments, long-term imag-
ing, tissue differentiation, immunostaining, “omics” analysis
of patterned tissue sections, mechanical characterization by
atomic-force microscopy, etc. Finally, the stability of the treat-
ment flow over several hours enables quantitative approaches
that seek to relate a complex spatiotemporal treatment with a
tissue response, a key step in the understanding of intracellu-
lar transduction pathways. This is particularly relevant to the
modelling and recapitulation of morphogenetic signalling,
necessary to attain a systems understanding of cell fate deter-
mination mechanisms during developmental organogenesis
or engineering of tissues for regenerative medicine.Acknowledgements
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